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Jemima Scott1,2*† , Tim Jones2,3†, Maria Theresa Redaniel2,3, Margaret T. May2, Yoav Ben-Shlomo2,3 and
Fergus Caskey1,2,4
Abstract
Background: The risk of acute kidney injury (AKI) attributable to renin angiotensin aldosterone (RAAS) inhibitors
and diuretics remains unclear.
Methods: We conducted a prospective cohort study using the Clinical Practice Research Datalink (2008–2015) linked
to Hospital Episode Statistics – Admitted Patient Care and Office for National Statistics mortality data. Patients were
included if they had one or more chronic diagnoses requiring medication. Exposed patients had a first ever
prescription for RAAS inhibitors/diuretics during the study period. AKI risk associated with exposure was determined by
multivariable Cox regression, propensity score-adjusted Cox regression and a prior event rate ratio (PERR) analysis.
Results: One hundred forty thousand nine hundred fifty-two individuals were included. Increased AKI risk in the
exposed group was demonstrated in both the multivariable and propensity score-adjusted cox regressions (HR 1.23
(95% CI 1.04–1.45) and HR 1.24 (1.05–1.47) respectively). The PERR analysis provided a similar overall hazard ratio with a
wider confidence interval (HR 1.29 (0.94–1.63)). The increased AKI risk in the exposed group was present only in those
receiving two or more antihypertensives. Absolute AKI risk was small.
Conclusions: RAAS inhibitors/diuretics result in an increased risk of AKI. The absolute increase in AKI risk is small,
however, and needs to be considered in the context of any potential benefits.
Keywords: Acute kidney injury, Diuretics, Renin-angiotension-aldosterone inhibitors
Background
The reported incidence of acute kidney injury (AKI) in
community-dwelling adults and hospital inpatients varies
significantly depending on the criteria used [1]. A recent
meta-analysis concluded that worldwide, one in five adults
and one in three children experience an episode of AKI
during an inpatient admission [2]. Studies in high-income
countries have reported an incidence of AKI of 522/100,000
people per year in the community, [3] and up to 22.7/100 in
an inpatient setting [4]. The incidence of AKI is likely to be
increasing [3, 5] due to an ageing population with increased
comorbidity and polypharmacy.
There is significant morbidity, mortality and economic
cost associated with AKI. A meta-analysis of adverse
outcomes following AKI conducted in 2009 [6] found
the risks of chronic kidney disease (CKD) and end-stage
kidney disease (ESKD) following a single episode of AKI
to be 7.8 and 4.9/100 patient-years, respectively. Even
mild AKI (a rise in serum creatinine of less than or equal
to 25%) was associated with a 70% increase in mortality.
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In 2014 the financial burden associated with AKI in the
United Kingdom (UK) was estimated to be £1.02 billion,
just over 1% of the annual National Health Service
budget [7].
AKI may result from reduced kidney perfusion, intrin-
sic renal disease or obstructive causes, with the first of
these accounting for 75% of AKI episodes in hospital
settings [8]. Risk factors include increasing age, sepsis,
hypotension and chronic conditions (diabetes mellitus,
congestive cardiac failure (CCF), CKD, atherosclerotic
peripheral vascular disease, liver disease) [9]. Certain
medications, including non-steroidal anti-inflammatories
(NSAIDs), diuretics and agents that inhibit the renin-
angiotensin-aldosterone (RAAS) axis have also been sug-
gested to increase the risk of AKI in epidemiological
studies, [10–12] however the absolute risk of AKI
amongst these individuals is unknown.
The absolute risk of AKI monsgt maintenance users of
RAAS inhibitors and diuretics is unknown. This study aims
to determine the absolute and relative risk of AKI in main-
tenance users of RAAS inhibitors and diuretics in a “real-
world” setting of community-dwelling comorbid adults.
Methods
Data source and population
We conducted a prospective cohort study using elec-
tronic medical records from the Clinical Practice Re-
search Datalink (CPRD) GOLD. At the time of data
extraction (July 2016), CPRD included records from 701
general practices in the UK, and over 16 million patients
[13]. The demographics of registered patients are repre-
sentative of the UK [14]. CPRD data have been validated,
audited, and quality checked [15]. Primary care data
from CPRD GOLD were linked to the Hospital Episode
Statistics – Admitted Patient Care (HES-APC) database,
Office for National Statistics Mortality data, and Indices
of Multiple Deprivation, as long as patients were eligible
for linkage (around 60% of CPRD patients). The study
protocol was approved by the Independent Scientific
Advisory Committee (ISAC) for MHRA Database Re-
search (protocol number: 16_030R).
Code lists
We defined our chronic conditions, outcome, exposure,
and covariables using medical and product codes within
CPRD, as well as values of specific blood test results.
Medical codes relate directly to clinical Read codes,
whilst product codes relate to the British National For-
mulary. Medications for chronic conditions were cross-
checked against European guidelines on classification of
medicines, [16] and by a clinical expert (F.C.). Addition-
ally, we used the International Classification of Diseases
(version 10) (ICD-10) to identify diagnosis of AKI in
HES-APC. Code lists are available from [https://github.
com/jonestim2002/aki_raas_diuretics].
Patients
We included patients from CPRD with indications of
any of five chronic conditions: CKD, diabetes, CCF,
hypertension, or ischaemic heart disease. Patients had to
have a valid month and year of birth, sex, and registra-
tion date. We required a reasonable ordering of events
for inclusion: diagnosis of first chronic condition after
the practice up-to-standard date (representing reason-
able quality of data collection from that practice); expos-
ure date after diagnosis of chronic condition; exit from
study after exposure date. We excluded patients with an
AKI diagnosis before index date; or those diagnosed
within 6 weeks after exposure, to account for patients
with a physiological drop in estimated GFR (eGFR) as a
result of the mechanism of RAAS inhibition.
Variables
Exposure
Exposed patients were those with a first ever prescrip-
tion for RAAS inhibitors or diuretics within the study
period (1st January 2008 until 30th September 2015).
The date of this first prescription is designated as the
index date. Unexposed patients did not have any pre-
scriptions for RAAS inhibitors or diuretics in their med-
ical records; they were matched (1:1) to the exposed
patients on age (within 3 years), sex, and time between
first chronic condition diagnosis and exposure date
(within 6months). Unexposed patients inherited the index
date of the exposed patient they were matched with. Pa-
tients had at least 18months of up-to-standard registra-
tion prior to their exposure date, to ensure that exposed
patients were new users of the medication and that suffi-
cient baseline covariable information was available. To ac-
count for differences in severity of disease between
groups, unexposed patients not receiving any medications
relevant to their chronic conditions were excluded.
Outcomes
Our outcome was AKI, as indicated by relevant medical
codes in CPRD GOLD (see code lists) or ICD-10 code
N17 in any diagnosis field of a hospital admission in the
linked HES data where available.
Covariables
Covariables included sex, age at index date, time since
diagnosis of first chronic condition, number of types of
relevant medications prescribed in the 18months before
index date (e.g. beta-blockers, calcium channel blockers,
etc.), number of General Practice (GP) consultations
(within 18months before index date), average systolic
blood pressure (within 18 months before index date),
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smoking status (most recent before index date), kidney
function (most recent eGFR before and up to 1 month
after index date), and binary flags representing each of
the five chronic conditions: CKD, diabetes mellitus,
CCF, hypertension, or ischaemic heart disease.
Follow-up
Patients were followed up until the earliest of the follow-
ing: first indication of AKI; death; transfer out from
practice; end of practice data collection; or end of the
study period (30th September 2015). Date of death was
taken from the ONS mortality records where available,
and otherwise from CPRD GOLD.
Statistical analyses
Main analyses
To estimate the association between prescription of
RAAS inhibitors and/or diuretics and AKI, we con-
ducted multivariable Cox regression, with AKI as our
event of interest. Covariables included sex, age, chronic
conditions (CKD, diabetes mellitus, CCF, hypertension,
ischaemic heart disease), duration of chronic condition,
number of medications, number of GP consultations,
systolic blood pressure, smoking and GFR. These covari-
ables are conceptualised as confounders due to their as-
sociation with AKI and potential exposure. As anyone
with an AKI within 6 weeks after index date was ex-
cluded, we started the time-to-event analysis at 6 weeks
after index date. We also investigated possible interac-
tions between exposure and number of medications as
such an interaction was found post-hoc in our complete
case analyses.
Missing covariable data
Some data were missing for smoking status, systolic
blood pressure, and renal function (see Table 1). We
conducted multiple imputation using chained equations
to account for the missing data in these covariables
using the ‘ice’ command in Stata. Twenty datasets were
imputed, with an imputation model that included the
outcome, exposure, and all covariables, as well as any
Fig. 1 Exclusions for exposed and unexposed cohorts
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appropriate interaction terms. Additionally, we con-
ducted a complete case analysis to compare our results.
To further address any confounding by indication, we
repeated the Cox regression analysis adjusting for con-
tinuous propensity scores [17], representing the patients’
propensity for being exposed given the values of other
covariables. The propensity score represented the pre-
dicted probability of treatment, based on a logistic regres-
sion model where exposure status (exposed/unexposed)
was regressed against the baseline covariables.
The number needed to treat (NNT) [18, 19] was calcu-
lated from the adjusted difference in survival between
groups, using the relevant baseline survival probability
for the unexposed group (at one, two and 3 years) and
appropriate adjusted hazard ratio from the multivariable
Cox regression.
Sensitivity analyses
To control for potential residual and unmeasured con-
founding, we carried out a prior event rate ratio analysis
(PERR) [20, 21]. For the PERR analysis, two unadjusted
Cox regressions were conducted: one to estimate the
hazard ratio for AKI in the period before exposure (i.e.
differences between the exposed/unexposed groups not
due to exposure), and another to estimate the hazard ra-
tio for AKI between the groups after exposure. The
PERR result is the ‘after’ hazard ratio divided by the
‘before’ hazard ratio, controlling for any differences
between the groups before exposure which might be
confounding (whether measured or unmeasured). As
such, this analysis required us to construct a slightly dif-
ferent matched dataset, where patients with AKI prior to
exposure were not excluded. We required patients to
have 3 years of registration prior to exposure, and cen-
sored follow-up at 3 years after exposure for the PERR
analysis. When checking the assumptions for the PERR
analysis, it was evident that the event rate for AKI in-
creased in the 6 months prior to exposure to RAAS in-
hibitors/ diuretics in patients in the exposed group. A
sensitivity analysis was therefore undertaken excluding
exposed and un-exposed patients experiencing an AKI
episode in that period.
Several additional sensitivity analyses were carried out.
These included (1) matching exposed patients to unex-
posed patients prescribed any other antihypertensive
within 6 months of the index date (Additional file 1), (2)
excluding patients with strong indications for RAAS
inhibition (proteinuric CKD and CCF) (Additional file 2),
(3) repeating the analysis in the subset of data linked to
HES (which provided information on ethnicity) and quin-
tiles of the Index of Multiple Deprivation (Additional files 3
and 4) comparing the risk of AKI in individuals
Table 2 Acute kidney injury rates (per 1000 person-years) by covariables (non-missing)
Exposed (n = 70,476) Unexposed (n = 70,476)
Overall Rate (95% CI)1 Rate (95% CI)
2.54 (2.34–2.76) 1.7 (1.53–1.89)
Gender Male Female Male Female
2.84 (2.56–3.15) 2.18 (1.91–2.48) 1.8 (1.57–2.07) 1.57 (1.33–1.84)
Age at
Exposure
< 65 65–74 > = 75 < 65 65–74 > = 75
1.82 (1.6–2.08) 2.8 (2.41–3.24) 4.35 (3.75–5.03) 1.22 (1.03–1.45) 1.82 (1.51–2.2) 2.99 (2.46–3.563)
Diagnosis to
Exposure
< 30 days 30–179 180–364 > = 365 < 30 days 30–179 180–364 > = 365
2.24 (1.95–2.59) 3.04 (2.45–3.77) 3.26 (2.41–4.41) 2.56 (2.28–2.89) 2.21 (1.62–3.03) 1.54 (1.28–1.84) 2.14 (1.54–2.98) 1.65 (1.41–1.93)
#
Medications
1 > = 2 1 > = 2
2.14 (1.89–2.42) 2.98 (2.67–3.31) 1.71 (1.53–1.92) 1.61 (1.22–2.13)
# GP
Consultation
< 10 10–19 20–29 > = 30 < 10 10–19 20–29 > = 30
1.9 (1.61–2.24) 2.31 (2–2.66) 3.12 (2.62–3.72) 3.9 (3.27–4.64) 1.18 (0.93–1.49) 1.57 (1.32–1.88) 2.01 (1.6–2.52) 2.71 (2.17–3.37)
Systolic
Blood
Pressure
< 120 120–139 140–159 > = 160 < 120 120–139 140–159 > = 160
4.66 3.18 2.19 2.19 1.37 1.77 1.73 1.34
Smoking Yes No Ex Yes (%) No (%) Ex (%)
2.63 2.05 3.01 2.09 1.49 1.73
GFR > = 60 45–59 < 45 > = 60 45–59 < 45
2.3 2.6 7.41 1.54 1.92 5.33
# Chronic
Conditions
1 > = 2 1 > = 2
2.27 (2.06–2.50) 3.61 (3.10–4.19) 1.58 (1.40–1.77) 2.64 (2.06–3.40)
1 Numbers in brackets are 95% confidence intervals
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Table 3 Cox Regression Models (n = 140,952)
Model Covariables HR (AKI) 95% LCI 95% UCI
Baseline1 Unexposed 1
Exposed 1.48 1.3 1.7
Baseline + Sex Unexposed 1
Exposed 1.48 1.3 1.7
Male 1
Female 0.81 0.71 0.92
Baseline + Age Unexposed 1
Exposed 1.48 1.29 1.69
< 65 years 1
65–74 1.53 1.31 1.79
> = 75 2.46 2.11 2.88
Baseline + Chronic Time Unexposed 1
Exposed 1.53 1.33 1.77
< 30 days 1
30–179 days 1.1 0.89 1.35
180–364 days 1.37 1.05 1.78
> = 365 days 1.05 0.89 1.24
Baseline + CKD Unexposed 1
Exposed 1.5 1.32 1.72
No CKD 1
CKD 1.93 1.63 2.27
Baseline + DM Unexposed 1
Exposed 1.41 1.24 1.61
No DM 1
DM 1.89 1.61 2.21
Baseline + HF Unexposed 1
Exposed 1.41 1.23 1.61
No HF 1
HF 3.65 2.74 4.86
Baseline + HT Unexposed 1
Exposed 1.59 1.39 1.82
No HT 1
HT 0.53 0.47 0.61
Baseline + IHD Unexposed 1
Exposed 1.5 1.31 1.71
No IHD 1
IHD 1.17 1 1.37
Baseline + Medications Unexposed 1
Exposed 1.37 1.19 1.58
1 1
> = 2 1.27 1.11 1.46
Baseline + GP Consultations Unexposed 1
Exposed 1.5 1.31 1.71
< 10 1
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prescribing RAAS inhibitors or diuretics alone, versus
those prescribe both (Additional file 4). All statistical ana-
lyses were conducted using Stata 14.
Results
Descriptive information
Between 1st January 2008 and 30th September 2015,
320,231 patients were prescribed their first ever RAAS
inhibitor or diuretic. After applying the inclusion/exclu-
sion criteria, 168,661 were available for matching, and
70,476 were matched to unexposed patients (Fig. 1
Exclusions for exposed and unexposed cohorts). Table 1
shows that the exposed and unexposed groups are well
matched on age and sex. The exposed group tended to
be on more types of medications for their conditions,
and were more hypertensive, but were otherwise similar.
Most of the missing data was for renal function.
Table 2 shows that rates of AKI (per 1000 person-
years) were higher amongst the exposed group than the
unexposed group. Rates were generally higher for men,
older age groups, people on more types of medication
(more notable in the exposed group), people having
Table 3 Cox Regression Models (n = 140,952) (Continued)
Model Covariables HR (AKI) 95% LCI 95% UCI
10–19 1.27 1.07 1.51
20–29 1.71 1.41 2.07
> = 30 2.23 1.84 2.71
Baseline + SBP Unexposed 1
Exposed 1.59 1.38 1.83
< 120 1
120–139 0.88 0.65 1.17
140–159 0.71 0.53 0.94
> = 160 0.68 0.5 0.92
Baseline + Smoking Unexposed 1
Exposed 1.48 1.3 1.69
No 1
Yes 1.35 1.13 1.6
Ex 1.34 1.16 1.54
Baseline + GFR Unexposed 1
Exposed 1.47 1.29 1.68
> = 60 1
45–59 1.29 1.07 1.55
< 45 2.92 2.2 3.88
Full Model Unexposed 1
Exposed 1.23 1.04 1.45
Full Model (inc meds*exposure) 1 (exposed) 1.1 0.91 1.33
> = 2 (exposed) 1.49 1.06 2.11
1 “Baseline” – hazard ratio prior to adjustment for covariable(s)
Table 4 Cox Regression Models adjusted by Propensity Scores for Disease Severity1 (n = 140,952)
Model Covariates HR (AKI) 95% LCI 95% UCI
Baseline Unexposed 1
Exposed 1.48 1.3 1.7
Baseline + P-Score (Full Model) Unexposed 1
Exposed 1.24 1.05 1.47
Full Model (inc meds*exposure) 1 (exposed) 1.09 0.89 1.33
> = 2 (exposed) 1.61 1.14 2.28
1 Variables in the propensity score model were: gender, age, time since first chronic condition, number of medications, number of GP consultations, chronic
condition flags, systolic blood pressure, kidney function (GFR), and smoking status
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more GP consultations, those with lower blood pressure
(more notable in the exposed group), smokers or ex-
smokers, people with worse renal function, and higher
for those with a specific chronic condition compared to
those without it for all conditions except hypertension.
Association between exposure to RAAS inhibitors/
diuretics and acute kidney injury
Main analyses
The results for the multivariable adjusted Cox regression
(Table 3) and the propensity score adjusted Cox regres-
sion (Table 4) showed an increased risk of AKI of 23–
24% following exposure to RAAS inhibitors / diuretics:
(multivariable cox regression HR = 1.23; 95% CI 1.04–
1.45 and propensity score HR = 1.24; 95% CI 1.05–1.47).
However, this was qualified by a significant interaction
between the exposure and the number of types of medi-
cation a patient was prescribed in the 18 months up to
exposure (p-value for 20 imputed datasets ranged be-
tween 0.0186 and 0.023. It appears that any additional
risk of AKI following RAAS inhibitors / diuretics occurs
in patients already taking other types of medications.
The numbers needed to treat with RAAS inhibitors/di-
uretics to observe one additional AKI event are pre-
sented in Appendix 1.
Sensitivity analyses
The PERR analysis, which additionally adjusts for un-
measured confounding, provided a similar overall haz-
ard ratio to the main analysis with a wider confidence
interval (HR = 1.29; 95% CI 0.94–1.63). AKI rates in
the two groups were not proportional in the period
leading up to exposure, with a notable increase in the
AKI rate in the exposed group in the 6 months prior
to exposure (Fig. 2 Acute kidney injury hazards in
time before exposure.). Non-proportionality was great-
est in those with the longest duration of diagnosis of
chronic condition. A sensitivity analysis was con-
ducted excluding patients with AKI in the 6 months
prior to exposure. This resulted in a higher PERR es-
timate (HR = 1.85; 95% CI 0.91–2.79), however confi-
dence intervals were wide.
Results for the complete case analyses were similar to
those using imputed data (data not shown). Analyses re-
stricted to the subset of data linked to HES which pro-
vided information on ethnicity and quintiles of the Index
of Multiple Deprivation gave similar results to the main
analyses (Additional file 3).
Discussion
This study demonstrated a significantly increased risk of
AKI in individuals taking RAAS inhibitors or diuretics in
the presence of any additional antihypertensive medica-
tion. There was, however, no association between AKI
risk and the number of antihypertensive medications in
the unexposed group. Despite a significantly increased
relative risk of AKI attributable to RAAS inhibition/diur-
etic use in the exposed group, the absolute risk of AKI
in these individuals was small. Further, as demonstrated
in the PERR analysis, we observed an increasing risk of
AKI in the months preceding initiation of RAAS inhib-
ition which has not previously been reported: Increased
Fig. 2 Acute kidney injury hazards in time before exposure
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risk in the exposed group was seen in those with the
longest duration of diagnosis of chronic condition. This
could be explained by a worsening of clinical condition
warranting initiation of further medication. Alternatively,
it could imply reverse causation whereby having an AKI
episode results in an increased likelihood of exposure to
RAAS inhibitors or diuretics, which needs consideration
in future observational studies of AKI risk.
The association between RAAS inhibitor/diuretic use
and AKI risk demonstrated in this study is consistent
with previous literature [10, 11, 22] and can be explained
biologically. RAAS inhibitors reduce tone in the efferent
arteriole of the glomerulus and thus impair renal auto-
regulation, maintenance of intraglomerular pressure and
glomerular filtration. Without directly targeting the
RAAS system, medication that lowers pre-glomerular
pressure by reducing the effective circulating volume ei-
ther by volume contraction (i.e. diuretics) is also likely
to increase the risk of AKI [23]. Glomerular filtration
pressure can also be very dependent on RAAS-mediated
chronic tone in the efferent arteriole in people with CCF
or renal artery stenosis, and those with disruptions to
the renal microcirculation, [24] making them further
sensitive to such effects.
Although this study demonstrated an increased risk of
AKI with RAAS inhibition/ diuretic use, the absolute
risk of AKI in the exposed group was low (2.5 and 1.7
events per 1000 person years in people taking RAAS in-
hibitors/ diuretics and those not, respectively). With a
small or even moderate effect of RAAS inhibition/diur-
etic on the risk of AKI the NNT will therefore be high.
In the subset of individuals with a creatinine >124umol/
L included in the HOPE randomised trial [25], the NNT
with Ramipril to prevent one myocardial infarction or
one stroke over 4.5 years was 20.4 and 16.1 respectively.
In the Acute Infarction Ramipril Efficacy study, a NNT
of 17.5 over 6–15 months was found to prevent all-cause
mortality in patients with heart failure following myocar-
dial infarction [26]. There is therefore substantial evi-
dence to support a beneficial impact of RAAS inhibition
in the prevention of ischaemic heart disease, CCF, cere-
brovascular disease, proteinuric CKD, ESKD, all-cause
and cardiovascular mortality [25–28]. As a result, RAAS
inhibitors have become the second most commonly pre-
scribed medication in General Practice (GP) in the UK,
accounting for 6% of all prescriptions [29].
Given this, any public health or individual patient level
recommendations about the initiation or temporary/
permanent discontinuation of RAAS inhibitors/ diuretics
must consider both the potential risk of harm as well as
benefit. The risk of AKI associated with RAAS inhibition
must be weighed against the potential benefits for each
individual, including delayed progression of CKD, [30]
reduction in cardiovascular events (myocardial infarc-
tion, cerebrovascular events, resistant heart failure fol-
lowing myocardial infarction) and mortality (all-cause
and cardiovascular-specific) [25, 26, 31]. The risk benefit
ratio is likely to be influenced by level of comorbidity as
well as concurrent medications [10]. In the general
population of the UK, the benefits of RAAS inhibition
are likely to outweigh the disadvantages in terms of AKI.
However, when prescribing RAAS inhibitors and di-
uretics, physicians should be aware that the risk of AKI
increases with number of additional hypertensive medi-
cations and diuretic use. The mechanism of the in-
creased risk is likely to relate to actual or relative
reduction in effective circulating volume; volume con-
traction and hypotension should therefore be avoided.
This study has several strengths and limitations. The
size of the cohort and geographical spread of recruit-
ment should enable the results to be generalisable to all
primary care populations in England. The exposed and
unexposed groups were well-matched, reducing bias,
and the use of multiple statistical models with similar re-
sults increase confidence in the effect estimate. In
addition, the results of this study support the majority of
existing literature in this area. However, the diagnosis of
AKI was based upon HES data/READ codes rather than
serum biochemistry, and AKI rates will therefore be
underestimated. The exclusion of individuals with an
AKI event prior to the index date or within 6 weeks of
initiation of RAAS inhibitors or diuretics was designed
to minimise baseline differences in AKI risk between
groups. However by doing so we may have inadvertently
excluded those with a higher risk of AKI. Medication
dose and dose changes were not explored in this ana-
lysis. This may be of particular relevance to RAAS inhib-
itors and diuretics where a dose-dependent impact on
renal function may be seen, and physiological changes in
measured function may therefore be interpreted as AKI
events. Further alternative explanations for our findings
include the possibility of increased testing of serum bio-
chemistry in the exposed group resulting in higher de-
tection of AKI. As with most observational studies there
is the possibility of residual confounding in the Cox and
propensity-matched analyses though this should have
been less of an issue in the PERR analysis.
Appendix
Table 5 Numbers needed to treat with renin angiotensin
aldosterone inhibitors or diuretics to observe one additional
acute kidney injury event
NNT
1 medication One year 6951
Three years 2370
2+ medications One year 966
Three years 336
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Conclusions
This study supports previous literature regarding an
increased risk of AKI in individuals prescribed RAAS
inhibitors and diuretics [10, 11, 22]. However, the re-
sults suggest the absolute increased risk in AKI is low
and limited to patients prescribed concurrent antihy-
pertensive medications. Further, the absolute risk of
AKI associated with RAAS inhibitors and diuretics is
low and likely to be significantly outweighed by the
multitude of beneficial effects demonstrated from
RAAS inhibition in the literature, [25, 30, 31] . Given
that the impact of sick day rules on patients’ adher-
ence to RAAS inhibitor/ diuretic treatment is un-
known, interventional studies are required to inform
practice that will optimise all patient outcomes, not
just AKI-related ones.
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